BiotechTube
PharmNovo

PharmNovo

Malmö, Sweden· Est.
pharmnovo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.2M

Overview

PharmNovo is a clinical-stage biotech developing first-in-class, selective delta opioid receptor agonists (DORAs) for neuropathic and chronic pain, a market with significant unmet need. The company's lead asset, PN6047, has completed Phase I studies and received CTA approval in Spain for a Phase IIa proof-of-concept trial in peripheral neuropathic pain. PharmNovo is a private company preparing for mid-stage clinical development, leveraging a novel mechanism intended to avoid the addictive properties and severe side effects of traditional opioids. Its strategy targets a large patient population underserved by current therapies.

Neuropathic PainChronic Pain

Technology Platform

Proprietary platform of selective delta opioid receptor agonists (DORAs) designed to provide analgesia without the addiction and side effects of mu-opioid receptor targeting.

Funding History

2
Total raised:$9.2M
Series A$8M
Seed$1.2M

Opportunities

The global neuropathic pain market represents a multi-billion dollar opportunity with severe unmet need due to the lack of safe, effective, non-addictive therapies.
Positive Phase II data for PN6047 could attract lucrative partnership deals with large pharma companies seeking to bolster their pain portfolios.
The ongoing opioid crisis creates a powerful tailwind for regulatory and commercial acceptance of a safer opioid alternative.

Risk Factors

The primary risk is clinical failure, as the delta-opioid receptor mechanism is novel and unproven for efficacy in human patients.
As a pre-revenue private company, PharmNovo faces significant financing risk and depends on raising capital to fund expensive clinical trials.
The competitive landscape includes numerous companies pursuing non-opioid and novel opioid mechanisms for pain.

Competitive Landscape

PharmNovo competes in the crowded chronic pain space, which includes developers of novel sodium channel inhibitors (e.g., NaV1.7), anti-NGF antibodies, and other non-opioid mechanisms. Its key differentiation is its first-in-class selective DORA approach, aiming to retain potent opioid-like efficacy while eliminating classic opioid liabilities. Success depends on proving this differentiation clinically.

More companies in Small Molecule Drugs →More companies in Sweden →